Safety and Durability of Sirolimus for Treatment of LAM

Summary

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

Eligibility

Inclusion Criteria:

* Female or male, age 18 or over
* Diagnosis of LAM based on ATS/JRS criteria
* Signed and dated informed consent
* On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy

Exclusion Criteria:

* Inability to attend at least one RLD Clinic visit per year
* Inability to give informed consent
* Inability or unwillingness to perform pulmonary function testing

Conditions3

Interventions2

Locations20 sites

Find trials near these locations

Related trials

• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 — Gustave Roussy, Cancer Campus, Grand Paris
• Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial — Central Hospital, Nancy, France
• Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. — Grupo Espanol de Tumores Neuroendocrinos
• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer — West China Hospital
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. — MedSIR
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors — Gustave Roussy, Cancer Campus, Grand Paris
• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype — Fudan University

Browse More Trials